- The agreement covers SB41, a potential biosimilar candidate referencing Fasenra® (benralizumab), and SB44, a potential biosimilar candidate referencing Ilaris® (canakinumab) with an option for 4 additional assets The partnership will cover development and
Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®[1] (benralizumab), and SB44, a biosimilar candidate referencing Ilaris®[2] (canakinumab).
Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory registration, and manufacture of the biosimilars, while Teva will be responsible for commercialization in global markets, including the United States (U.S.), Europe, and Canada. The companies have agreed to an option for expanding the partnership to other territories.
This agreement reinforces the long-standing and successful partnership between Samsung Bioepis and Teva, which has already resulted in the successful commercialization of EPYSQLI® (eculizumab-aagh) in the U.S. The companies have also expanded that agreement further to include OPUVIZ® (aflibercept) in Canada. The expanded collaboration reflects a shared approach to combining complementary capabilities for broadening access to biosimilar medicines across global markets.
“We are thrilled to expand our successful partnership with Teva with these new biosimilar candidates. This agreement marks another milestone in our shared journey to improve patient access to life-changing medicines,” said Kyung-Ah Kim, President and Chief Executive Officer at Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and healthcare systems across the world.”
Richard Francis, President and CEO of Teva said, “Biosimilars are an increasingly important part of our Pivot to Growth strategy and our ambition to transform into a leading biopharmaceutical company. This global multi-product agreement is a significant step in scaling our biosimilars business, adding greater breadth to our pipeline and building on the strong foundation we have established with Samsung Bioepis in the U.S. By combining a strong and growing portfolio and our excellent global commercial capabilities, we are strengthening our leadership position in biosimilars and our ability to bring more treatment options to patients around the world.”
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings (KRX: 0126Z0), Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit https://www.tevapharm.com.
Teva Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully execute the license, development and commercialization agreement with Samsung Bioepis; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ending December 31, 2025, including in the section captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
[1] Fasenra is a trademark of AstraZeneca AB.
[2] Ilaris is a trademark of Novartis AG.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261001835078/en/
언론연락처:
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory registration, and manufacture of the biosimilars, while Teva will be responsible for commercialization in global markets, including the United States (U.S.), Europe, and Canada. The companies have agreed to an option for expanding the partnership to other territories.
This agreement reinforces the long-standing and successful partnership between Samsung Bioepis and Teva, which has already resulted in the successful commercialization of EPYSQLI® (eculizumab-aagh) in the U.S. The companies have also expanded that agreement further to include OPUVIZ® (aflibercept) in Canada. The expanded collaboration reflects a shared approach to combining complementary capabilities for broadening access to biosimilar medicines across global markets.
“We are thrilled to expand our successful partnership with Teva with these new biosimilar candidates. This agreement marks another milestone in our shared journey to improve patient access to life-changing medicines,” said Kyung-Ah Kim, President and Chief Executive Officer at Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and healthcare systems across the world.”
Richard Francis, President and CEO of Teva said, “Biosimilars are an increasingly important part of our Pivot to Growth strategy and our ambition to transform into a leading biopharmaceutical company. This global multi-product agreement is a significant step in scaling our biosimilars business, adding greater breadth to our pipeline and building on the strong foundation we have established with Samsung Bioepis in the U.S. By combining a strong and growing portfolio and our excellent global commercial capabilities, we are strengthening our leadership position in biosimilars and our ability to bring more treatment options to patients around the world.”
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings (KRX: 0126Z0), Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit https://www.tevapharm.com.
Teva Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully execute the license, development and commercialization agreement with Samsung Bioepis; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ending December 31, 2025, including in the section captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
[1] Fasenra is a trademark of AstraZeneca AB.
[2] Ilaris is a trademark of Novartis AG.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261001835078/en/
언론연락처:
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
ⓒ DNN & dnnkorea.kr 무단전재-재배포금지
BEST 뉴스
-
남수단 대통령 특사 방한… 한국·남수단 협력의 새 장 열다
이태석재단을 방문한 아둣 살바 키르 마야르디트 남수단 특사와 대표단이태석 신부의 사랑과 헌신으로 시작된 한국과 남수단의 인연이 양국의 실질적인 협력으로 이어지고 있다. 이태석재단(이사장 구수환)은 살바 키르 남수단 대통령의 장녀인 아둣 살바 키르 마야르디트 대통령 특사를 초청해 3박 4일간의 방한 일정... -
도봉노인종합복지관, 개관 26주년 기념 ‘도봉 어르신 문화축제’ 성료
도봉 어르신 문화축제 전경서울시립도봉노인종합복지관(관장 이은주)은 개관 26주년 및 노인의 날을 맞아 지난 10월 13일(화) 지역 어르신과 주민 약 1000명이 참여한 가운데 2026년 도봉 어르신 문화축제 ‘스스로 스마트를 즐기자!’를 성황리에 마쳤다고 밝혔다. 이번 축제는 스마트 기기와 AI 기술이 보편화되는 시대... -
국화꽃처럼 활짝 핀 웃음꽃… 디엔엔 사회적협동조합, 장애인과 함께한 행복한 가을 나들이
디엔엔 사회적협동조합(이사장 이채현)은 지난 11월 4일(수) 오전 11시, 장애인들과 함께 제26회 마산가고파국화축제 현장을 찾아 지역사회 탐방 행사를 진행했다. 이번 행사는 장애인들이 지역의 대표적인 문화축제를 직접 경험하고, 아름다운 자연과 문화를 함께 즐기며 지역사회 구성원으로서... -
한국자폐인사랑협회, 제1회 공익활동 임팩트 어워드 ‘행정안전부 장관상’ 수상
오른쪽부터 한국자폐인사랑협회 김용직 회장과 윤호중 행정안전부 장관이 대한민국 공익활동 임팩트 어워드 한국자폐인사랑협회 ‘행정안전부장관상 표창’ 기념 촬영을 하고 있다한국자폐인사랑협회(회장 김용직, 이하 ‘사랑협회’)는 10월 14일(수) 서울 여의도 FKI타워에서 개최된 ‘제1회 대한민국 공익활동 임팩트 어워... -
발달장애인과 함께하는 우리 동네 환경사랑! 산호동 줍킹 봉사활동
2026년 11월 6일(금) 오전, 디엔엔사회적협동조합은 봉사활동의 일환으로 발달장애인들과 함께 창원시 마산합포구 산호동 일대에서 '줍킹' 활동을 진행했다. 이번 활동은 발달장애인들이 지역사회의 일원으로서 환경보호에 직접 참여하고, 건강한 신체활동과 봉사활동을 통해 지역사회 참여... -
한국자폐인사랑협회, 발달장애인 재산관리지원서비스 성과보고회 성료
한국자폐인사랑협회, 발달장애인 재산관리지원서비스 성과보고회한국자폐인사랑협회(회장 김용직, 이하 ‘사랑협회’)는 10월 16일(금) 오후 2시 서울 여의도 이룸센터 누리홀에서 ‘2026년 한국자폐인사랑협회 재산관리지원서비스 성과보고회’를 개최했다고 밝혔다. 이번 성과보고회는 ‘발달장애인 재산관리 전문지원체계...
전체댓글 0
NEWS TOP 5
실시간뉴스
추천뉴스
포토뉴스
more +-
DNN 사회적협동조합·DNNKOREA.KR 출범
함께 꿈꾸는 미래’ 장애인과 지역사회의 눈이 되다… DNN 사회적협동조합·DNNKOREA.KR 출범 기업의 존재 이유를 단순한 ‘이윤 창출’에서 ‘사회적 가치 창출’로 과감히 전환하며 귀감이 되고 있는 기업이 있다. 지난 2024년 10월, 기업의 궁극적 목표를 사회공헌에 두고 장애인표준사업장을 설립하며 포용적 고용 생태계... -
고용노동부 근로감독관, A업체 ‘퇴직금 산정 오류’ 시정조치… 고용계약서 휴무일 기준도 명확히 정비
[현장포커스] 고용노동부 근로감독관, A업체 ‘퇴직금 산정 오류’ 시정조치… 고용계약서 휴무일 기준도 명확히 정비 고용노동부 소속 근로감독관(특별사법경찰관)이 관내 사업장을 대상으로 실시한 근로감독에서 A업체가 퇴직금을 법적 기준과 다르게 산정해 지급한 사실이 적발되어 시정조치를 받았다. 아울러 고용계약... -
진주교육청, 사회적 약자 기업의 판로 개척 및 상생 협력 기반 마련 간담회 개최
“사회적 약자 기업, 공공조달 실질적 경쟁력 확보 위해 제도 개선 시급” 진주교육지원청 간담회서 오세록 가림건설 조은창 대표, 구조적 한계 지적 가격 경쟁 비중 낮추고 ‘약자 지원·지역 업체’ 배점 확대 제안 [진주=DNN뉴스] 공공조달 시장에서 사회적 약자 기업이 실질적인 경쟁력을 확보할 수 있도록 제도를... -
“함께 꿈꾸는 미래” 디엔엔사회적협동조합, 새로운 출발
이채현 초대 이사장 중심으로 힘찬 출범… 장애인과 비장애인이 함께하는 사회적 가치 실현 디엔엔사회적협동조합이 ‘함께 꿈꾸는 미래’를 기치로 내걸고 새로운 출발을 알렸다. 디엔엔사회적협동조합은 최근 조합원들이 한자리에 모인 가운데 출범을 기념하고 앞으로의 활동 방향과 비전을 공유했다. 이날 참석자...
